MyDrHank review

MyDrHank prices its GLP-1s on a four-rung ladder, and the rung it shows you is always the cheapest one. Compounded tirzepatide is $349 a month billed monthly, $297 on a quarter, $267 on six months and $240 on a year paid up front. Injectable semaglutide runs $259, $220, $198 and $178. The oral tablet runs $249, $212, $190 and $171. Those are the real numbers, read out of the site's own code on August 28, 2026.

What the site displays is a different thing. The component that renders a price takes the whole ladder and reduces it to its minimum before printing "From $X/mo" — so the figure on the page is the twelve-month rung by construction, every time, for every product. The month-to-month rate you would pay if you signed up today is not shown on any page of the funnel. It exists, it is current, and you cannot see it until you are inside checkout.

That construction produces a claim worth reading twice. The FAQ answers "How much does the program cost?" with "Plans start at $171/mo with no contract" — but $171 is the annual prepay rate, $2,057 charged at once. A year bought in advance is not the absence of a contract; it is the most committed version of one. The month-to-month plan, the one that genuinely has no contract, costs $249 for the same product.

A pricing footnote goes further and advertises a plan that exists nowhere: "Plans start at $171/mo for compounded semaglutide and $200/mo for compounded tirzepatide." No tirzepatide rung costs $200 — the cheapest is $240, and that one requires $2,883 up front. The $171 belongs to the oral tablet; injectable semaglutide's annual rate is $178. Two of the three figures in that sentence do not describe a purchase a reader can make.

The rest of the operation is better than that makes it sound, and the good part is unusually good. The dose-flat promise is real and the company states it plainly — "The price stays the same at every dose — no surprise price increases" — which matters more than most headline rates, because titrating to a maintenance dose is where GLP-1 bills usually climb. Every rung and every up-front total is published before any intake questionnaire. There is an oral semaglutide route, including a version compounded with low-dose ondansetron to blunt the nausea that ends most GLP-1 courses early. And the company is clean against the FDA warning-letter database under its brand, its corporate entity and its domain, with "Dr. Hank, LLC" credited in its own terms — more corporate disclosure than most of this market offers.

Two absences to weigh before buying. The consumer site publishes no list of states it serves; the six it excludes are named only in its affiliate terms, which is not a document a patient would think to read. And no compounding pharmacy is named beyond "an FDA-registered U.S. pharmacy," so the company that actually makes the drug is not something you can check. Note too that the dose-flat promise is GLP-1 only — the NAD+ and sermorelin lines say the opposite, that final pricing depends on the dose prescribed.